# BALANCE+ Vanguard Phase

> **NCT05893147** · NA · COMPLETED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 174 (actual)

## Conditions studied

- Gram-negative Bacteremia

## Interventions

- **OTHER:** De-escalation VS No De-escalation
- **OTHER:** Oral beta-lactams VS non beta-lactams
- **OTHER:** Central vascular catheter retention VS Central vascular catheter replacement
- **OTHER:** Cephalosporin VS Carbapenem for low risk AmpC organisms
- **OTHER:** Routine follow-up blood culture VS No routine follow-up blood culture

## Key facts

- **NCT ID:** NCT05893147
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-26
- **Primary completion:** 2024-07-23
- **Final completion:** 2024-08-10
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05893147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05893147, "BALANCE+ Vanguard Phase". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05893147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*